Bromazolam: What It Is, Dangers & Overdose Risk

Bromazolam is a designer benzodiazepines structurally related to Xanax.

It is synthesized in the 1970s and never approved for medical use. It became one of the most lethal drugs in the illicit drug supply before the DEA placed it in Schedule I on a temporary emergency basis in December 2025.

Bromazolam produces potent GABA-A receptor depression, carries a high risk of fatal respiratory failure when combined with opioids, and does not respond to naloxone reversal.

Between April 2021 and July 2025, the DEA detected bromazolam in 240 forensic toxicology cases. Fatalities occurred in 189 of those cases, a mortality rate of 79% among identified exposures.

Key Takeaways

• According to the Federal Register (December 2025), the DEA’s toxicology program detected bromazolam in 240 cases between April 2021 and July 2025, with fatalities observed in 189 of those cases. Polydrug use involving fentanyl was present in 82% of bromazolam-associated deaths in a Travis County, Texas study of 112 cases.
• Bromazolam was placed in Schedule I of the Controlled Substances Act on a temporary emergency basis by the DEA in December 2025, making manufacture, distribution, and possession without authorization a federal criminal offense.
• Naloxone (Narcan) is ineffective against benzodiazepine overdose including bromazolam. Opioid overdose reversal agents do not reverse GABA-A receptor depression, meaning bystander administration of naloxone will not prevent death from bromazolam respiratory failure.
• Law enforcement seizures of bromazolam in the United States increased from fewer than 3 per year during 2016 to 2018, to 2,142 in 2022 and 2,913 in 2023, per CDC MMWR data published in January 2024.

What Is Bromazolam?

Bromazolam is a triazolobenzodiazepine, a subclass of designer benzodiazepines but never evaluated or approved for human therapeutic use. It was first synthesized during pharmaceutical research in the 1970s under the compound designation XLI-268 before being abandoned by drug developers.

Bromazolam as a Designer Benzodiazepine

Designer benzodiazepines (DBZDs) are synthesized to mimic the pharmacological effects of clinically approved benzodiazepines while remaining outside existing scheduling frameworks. Bromazolam specifically is the brominated counterpart to alprazolam, differing in the substitution of a bromine atom for a chlorine atom on the diazepine ring. This structural modification alters the potency, half-life, and metabolite profile compared to alprazolam while preserving the GABA-A receptor binding mechanism responsible for its sedative, anxiolytic, and respiratory depressant effects.

Bromazolam vs Bromazepam: Critical Distinction

Bromazolam and bromazepam are two different drugs that are frequently confused due to similar names. Bromazepam is a conventional 1,4-benzodiazepine prescribed in Europe and Canada under the brand name Lectopam for anxiety and seizure disorders. It is not available in the United States. Bromazolam is a designer triazolobenzodiazepine that was never approved for therapeutic use anywhere and has never been prescribed medically. When assessing any exposure or reported use, clinicians must confirm which compound is involved, as the clinical management and legal implications are different.

DSM-5-TR Classification

Problematic bromazolam use is classified under Sedative, Hypnotic, or Anxiolytic Use Disorder (DSM-5-TR) within the class of benzodiazepine-type substances. The disorder is diagnosed when recurrent bromazolam use produces clinically significant impairment across 11 criteria including tolerance, withdrawal, craving, and continued use despite adverse consequences. Severity specifiers mirror other substance use disorders: mild (2 to 3 criteria), moderate (4 to 5 criteria), and severe (6 or more criteria).

How Bromazolam Works in the Brain

Bromazolam produces central nervous system depression through positive allosteric modulation of GABA-A receptors, the same mechanism shared by all benzodiazepines, alcohol, and barbiturates.

GABA-A Receptor Mechanism

GABA-A receptors are ligand-gated chloride ion channels that mediate inhibitory neurotransmission throughout the brain and spinal cord. Bromazolam binds to a specific site on the GABA-A receptor complex and amplifies the effect of endogenous gamma-aminobutyric acid (GABA), increasing the frequency of chloride channel opening. Elevated intracellular chloride hyperpolarizes neurons, reducing their firing rate across the brainstem, limbic system, cerebral cortex, and spinal cord. This produces sedation, anxiolysis, muscle relaxation, anticonvulsant activity, and, at high doses, respiratory depression.

Potency and Half-Life

Bromazolam is substantially more potent than diazepam on a milligram-per-milligram basis and has a prolonged elimination half-life estimated between 10 and 20 hours, longer than alprazolam’s 6 to 12 hours. The extended half-life means sedation and respiratory depression persist for many hours beyond the user’s subjective experience of intoxication, creating a delayed overdose risk that is particularly dangerous when combined with subsequent opioid use.

Tolerance, Dependence, and Neuroadaptation

Chronic bromazolam use drives GABA-A receptor subunit downregulation and reduced receptor sensitivity, producing tolerance and physical dependence. Abrupt cessation or dose reduction in dependent individuals triggers compensatory central nervous system hyperexcitability that manifests as anxiety, tremors, sweating, and seizures through mechanisms identical to alcohol withdrawal.

Bromazolam Legal Status

Bromazolam’s legal status changed dramatically in late 2025 following years of escalating overdose deaths and 21-state coalition pressure on the DEA to act.

The December 2025 DEA Emergency Scheduling

The DEA published a final rule in the Federal Register on December 15, 2025, temporarily placing bromazolam in Schedule I of the Controlled Substances Act. The temporary scheduling designation, which carries the same criminal penalties as permanent Schedule I substances, was authorized under the DEA’s emergency scheduling authority based on evidence of high abuse potential, imminent hazard to public safety, and 189 documented fatalities in the agency’s toxicology data. The temporary placement remains in effect for two years while permanent scheduling procedures proceed.

Prior State-Level Bans

Before the federal action, multiple states had independently banned bromazolam through state analog acts, drug scheduling orders, or explicit legislative prohibitions. Pennsylvania, which recorded 59 designer benzodiazepine deaths in 2022 rising to 147 in 2023, was among the states pushing for federal scheduling. In August 2025, a 21-state coalition of Attorneys General sent a formal letter to the DEA urging immediate emergency action.

International Classification

The World Health Organization placed bromazolam under Schedule IV of the Convention on Psychotropic Substances in March 2024, recommending international control measures. This WHO classification preceded the US federal action and reflected similar concerns about polydrug lethality, rapidly growing illicit supply, and absence of legitimate medical use.

Dangers and Overdose Risk

Bromazolam overdose is a medical emergency producing life-threatening respiratory depression that does not respond to standard overdose reversal agents.

Common Signs of Bromazolam Use

Common signs of acute bromazolam intoxication include:

• Sedation and drowsiness: Excessive sedation disproportionate to any prescribed medication, with difficulty staying awake in conversation.
• Slurred speech and ataxia: GABA-A mediated motor coordination impairment produces slurred speech, stumbling, and wide-based gait similar to severe alcohol intoxication.
• Anterograde amnesia: Bromazolam inhibits hippocampal memory consolidation, producing blackout episodes where users have no recall of events that occurred during intoxication.
• Muscle weakness and hypotonia: Spinal cord GABA-A activation produces generalized muscle relaxation and reduced grip strength.
• Reduced respiratory rate: Brainstem GABA-A activation suppresses central respiratory drive, producing slow, shallow breathing that signals early overdose risk.

Severe Overdose Symptoms

Severe overdose symptoms require immediate emergency response:

• Respiratory depression: Breathing rate below 12 per minute or prolonged pauses signal life-threatening respiratory failure requiring airway support.
• Coma and unresponsiveness: Deep sedation with no response to voice or sternal rub indicates CNS depression severe enough to require intubation and mechanical ventilation.
• Hypoxia and cyanosis: Blue discoloration of lips and fingertips reflects critically low blood oxygen from failed respiration.
• Cardiovascular collapse: Profound hypotension and bradycardia develop in severe overdoses, particularly when bromazolam is combined with opioids, alcohol, or other CNS depressants.

Call 911 immediately for any person who is unresponsive, has slow or absent breathing, or cannot be roused. Naloxone will not reverse bromazolam overdose. Only intubation, mechanical ventilation, and supportive ICU care can prevent death from pure benzodiazepine respiratory failure.

Long-Term Effects and Complications

Sustained bromazolam use produces progressive neurological and psychological deterioration:

• Cognitive impairment: Chronic GABA-A suppression produces persistent deficits in memory, processing speed, and executive function that can persist 6 to 12 months after cessation in heavy users.
• Severe physical dependence: Bromazolam dependence develops rapidly due to potency and produces life-threatening withdrawal seizures on abrupt cessation without medical supervision.
• Depression and anhedonia: Chronic GABA-A downregulation drives persistent low mood, emotional blunting, and anhedonia that outlasts the acute withdrawal phase.
• Polysubstance use escalation: The Travis County study identified fentanyl co-use in 82% of bromazolam deaths, and methamphetamine in 41%, reflecting the polysubstance patterns common in people who use unregulated designer benzodiazepines.

Bromazolam and Drug Testing

Bromazolam detection requires specific toxicology methods that are not included in most standard workplace or clinical drug panels.

Standard Immunoassay Screening

Standard urine immunoassay panels test for the benzodiazepine drug class using antibodies calibrated to common metabolites like oxazepam. Bromazolam may or may not trigger a positive benzodiazepine result on standard immunoassay because its metabolite profile differs from the compounds the antibodies are designed to detect. A negative result on standard immunoassay does not rule out bromazolam use.

Confirmatory Testing

Liquid chromatography-mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) can identify bromazolam and its specific metabolites by molecular weight and fragmentation pattern. Forensic toxicology laboratories, addiction medicine programs, and medical examiners have access to these methods. Standard clinical urine drug screens do not confirm or exclude bromazolam without specific method inclusion.

How to Treat Bromazolam Dependence

Bromazolam dependence requires medically supervised treatment, as withdrawal from high-dose benzodiazepines carries seizure risk that is fatal without proper management.

Medical Detoxification

Medical detox under physician oversight is the mandatory first step for bromazolam dependence. Clinicians use long-acting benzodiazepines such as diazepam or chlordiazepoxide to substitute and then taper, preventing the sudden receptor denervation that produces withdrawal seizures. The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) measures withdrawal severity across 20 domains and guides dosing decisions during the taper protocol.

First-Line Behavioral Therapies

Cognitive behavioral therapy (CBT) for sedative use disorder targets the cognitive patterns, emotional triggers, and avoidance behaviors maintaining benzodiazepine use disorder. CBT combined with relapse prevention skill building reduces the return to use that characterizes the high-pressure early months of benzo recovery. Xanax and alprazolam misuse shares similar clinical presentation and responds to the same CBT protocols used for bromazolam recovery.

Pharmacological Management

Beyond the taper protocol, clinicians address co-occurring anxiety and insomnia with non-benzo alternatives including buspirone for generalized anxiety and trazodone or quetiapine for sleep. SSRIs such as sertraline and escitalopram treat the underlying anxiety and depressive disorders that frequently drove the initial benzodiazepine use. Mood stabilizers such as valproate provide anticonvulsant coverage in patients with particularly high seizure risk.

Emerging and Adjunct Treatments

Flumazenil, a competitive GABA-A receptor antagonist, reverses acute benzodiazepine intoxication and is used in emergency settings but has a shorter half-life than bromazolam, requiring repeat dosing. Low-dose flumazenil infusion protocols are under clinical investigation as detox adjuncts that reduce the severity of benzodiazepine withdrawal symptoms. Neurofeedback therapy, available at Olympic Behavioral Health, targets the dysregulated cortical activity patterns that persist after benzodiazepine cessation.

Treatment at Olympic Behavioral Health

Olympic Behavioral Health treats benzodiazepine use disorder, including presentations involving designer benzodiazepines such as bromazolam, within a medically supervised framework that addresses both the physiological dependence and the co-occurring mental health conditions driving the use.

Medical Detox

Medical detox referal by Olympic Behavioral Health is supervised by Dr. Nvari, Medical Director and board-certified psychiatrist, alongside Sabina, board-certified psychiatric ARNP. The medical team manages benzodiazepine taper protocols using CIWA-B monitoring and adjusts dosing in real time to prevent seizures while minimizing over-sedation. Clients receive daily physician contact during the acute detoxification phase.

Partial Hospitalization Program

The partial hospitalization program delivers six hours of daily clinical programming following medical stabilization. PHP combines individual weekly therapy with group psychoeducation on benzodiazepine pharmacology, relapse triggers, and long-term recovery planning. Psychiatric medication management for co-occurring anxiety, depression, or PTSD is integrated throughout the PHP phase.

Intensive Outpatient and Dual Diagnosis

The intensive outpatient program continues evidence-based recovery work after PHP. The dual diagnosis track addresses the anxiety disorders, trauma histories, and depressive disorders that frequently co-occur with benzodiazepine dependence, treating both conditions simultaneously rather than sequentially. Structured relapse prevention programming continues throughout both levels of care.

Same-day clinical assessments are available for adults ready to begin treatment.

Frequently Asked Questions

1- Is bromazolam legal in the US?

No. Bromazolam was placed in Schedule I of the Controlled Substances Act by the DEA through emergency temporary scheduling in December 2025. Schedule I classification makes manufacture, distribution, and possession without authorization a federal criminal offense. Prior to December 2025, bromazolam was not federally scheduled, though multiple states had banned it through state analog acts and scheduling orders.

2- Is bromazepam stronger than Xanax?

Bromazepam and bromazolam are different drugs. Bromazepam is a conventional benzodiazepine prescribed in Europe and Canada for anxiety and seizure disorders that is not available in the United States. It has intermediate potency broadly comparable to diazepam. Bromazolam is a designer benzodiazepine never approved for therapeutic use that is significantly more potent than alprazolam (Xanax) on a milligram-per-milligram basis and carries substantially higher overdose risk.

3- What is bromazepam used for?

Bromazepam (Lectopam) is prescribed in European and Canadian medical practice for the short-term management of anxiety disorders, panic disorder, and pre-procedural sedation. It belongs to the 1,4-benzodiazepine class and works through GABA-A receptor potentiation. It is not available in the United States and is not the same compound as the designer drug bromazolam.

4- Will bromazolam show on a drug test?

Standard urine immunoassay panels may not reliably detect bromazolam because its metabolite profile differs from the calibrated benzodiazepine reference compounds used in most commercial screening tests. Liquid chromatography-mass spectrometry (LC-MS/MS) can identify bromazolam and its specific metabolites. A negative result on a standard benzodiazepine urine screen does not rule out bromazolam use without confirmatory mass spectrometry testing.

5- What happens when you mix bromazolam and opioids?

Combining bromazolam with opioids such as fentanyl, heroin, or oxycodone produces synergistic CNS and respiratory depression that dramatically amplifies fatal overdose risk. Both drug classes independently suppress breathing; together they produce respiratory failure at doses that would be survivable separately. The Travis County study found fentanyl present in 82% of bromazolam-associated deaths. Naloxone reverses the opioid component but has no effect on the benzodiazepine-driven respiratory depression.

6- Can bromazolam withdrawal be life-threatening?

Yes. Abrupt cessation of bromazolam in physically dependent individuals produces benzodiazepine withdrawal syndrome, which can progress to generalized tonic-clonic seizures and status epilepticus without medical management. Withdrawal severity depends on dose, duration of use, and individual neurological vulnerability. Medical detoxification with CIWA-B monitoring and a supervised benzodiazepine taper is the standard of care for anyone physically dependent on bromazolam or other potent benzodiazepines.

References

1. Drug Enforcement Administration. (2025). Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I. Federal Register, 90(240). Retrieved from https://www.federalregister.gov
2. Ehlers, P. F., Deitche, A., Wise, L. M., et al. (2024). Seizures, Hyperthermia, and Myocardial Injury in Three Cases of Bromazolam Overdose. MMWR Morbidity and Mortality Weekly Report, 72(52-53), Centers for Disease Control and Prevention.
3. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). APA Publishing.
4. World Health Organization. (2024). Bromazolam: Critical Review and Pre-Review. Expert Committee on Drug Dependence. Geneva: WHO.
5. Pennsylvania Department of Health. (2024). Health Advisory 763: Emerging Substances in the Drug Supply Including Designer Benzodiazepines and Nitazenes. Harrisburg: PA DOH.
6. National Institute on Drug Abuse. (2024). Benzodiazepines and Opioids. Retrieved from https://nida.nih.gov/research-topics/opioids/benzodiazepines-opioids
7. Sulim, A., Harris, M. T., et al. (2023). Retrospective study of bromazolam-related deaths in Travis County, Texas. Journal of Analytical Toxicology. PMID reference on file.
8. Centers for Disease Control and Prevention. (2024). Drug Overdose Deaths in the United States. Retrieved from https://www.cdc.gov/nchs/fastats/drug-overdoses.htm